

Glucocorticoids, Inhaled Review

3/05/2009

Copyright © 2004 - 2009 by Provider Synergies, L.L.C. All rights reserved.
Printed in the United States of America.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

*Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
5181 Natorp Blvd., Suite 205
Mason, Ohio 45040*

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Comments and suggestions may be sent to Editor@providersynergies.com.



Glucocorticoids, Inhaled Review

FDA-Approved Indications

Drug	Manufacturer	Indication(s)
Corticosteroids		
beclomethasone inhalation aerosol (QVAR™) ¹	IVAX	<ul style="list-style-type: none"> Maintenance treatment of asthma as prophylactic therapy (see indicated ages below for each product) For asthma patients requiring systemic corticosteroid administration to reduce or eliminate the need for oral systemic corticosteroids <p><u>Indicated Ages</u></p> <ul style="list-style-type: none"> QVAR is for use in patients age five and older Pulmicort Flexhaler is for use in patients age six and older. Aerobid and Aerobid-M are for use in patients age six and older. Flovent HFA and Flovent Diskus are for use in patients age four and older. Asmanex is for use in patients age four and older. Azmacort is for use in patients age six and older.
budesonide inhalation powder (Pulmicort Flexhaler®) ²	AstraZeneca	
flunisolide inhalation aerosol (Aerobid® ¹ , Aerobid-M®) ³	Forest	
fluticasone inhalation powder (Flovent Diskus®) ⁴	GlaxoSmithKline	
fluticasone inhalation aerosol (Flovent HFA®) ⁵	GlaxoSmithKline	
mometasone furoate inhalation powder (Asmanex® Twisthaler) ⁶	Schering-Plough	
triamcinolone inhalation aerosol (Azmacort®) ⁷	Abbott	
budesonide inhalation suspension (Pulmicort Respules®) ⁸	AstraZeneca	<ul style="list-style-type: none"> Maintenance treatment of asthma as prophylactic therapy in patients 12 months to eight years of age
ciclesonide inhalation aerosol (Alvesco®) ⁹	Nycomed US Inc.	<ul style="list-style-type: none"> Maintenance treatment of asthma as prophylactic therapy in patients in adult and adolescent patients 12 years of age and older
Corticosteroid/Bronchodilator combinations		
budesonide / formoterol inhalation aerosol (Symbicort®) ¹⁰	AstraZeneca	<ul style="list-style-type: none"> Maintenance treatment of asthma in patients 12 years of age and older Maintenance treatment of airflow obstruction in patients with COPD
fluticasone / salmeterol inhalation powder (Advair® Diskus) ¹¹	GlaxoSmithKline	<ul style="list-style-type: none"> Maintenance treatment of asthma in patients four years of age and older Maintenance treatment of airflow obstruction in COPD including chronic bronchitis and emphysema (250/50 only). To reduce COPD exacerbations in patients with a history of exacerbations (250/50 only).
fluticasone / salmeterol inhalation aerosol (Advair® HFA) ¹²	GlaxoSmithKline	<ul style="list-style-type: none"> Maintenance treatment of asthma in patients 12 years of age and older

Overview

The National Asthma Education and Prevention Program (NAEPP) has defined asthma as a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role.¹³ In susceptible individuals, inflammation may cause recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These episodes are usually associated with airflow obstruction that is often reversible either spontaneously or with treatment. The inflammation also causes an increase in bronchial hyper-responsiveness to a variety of stimuli.

Studies have demonstrated the efficacy of inhaled corticosteroids (ICS) in improving lung function, reducing symptoms, reducing frequency and severity of exacerbations, and improving the quality of life (QoL) of patients with asthma.^{14,15,16,17,18} Based on this evidence, the 2007 National Heart, Lung, and Blood Institute, National Institutes of Health (NHLBI, NIH) Global Initiative for Asthma (GINA) state that “inhaled glucocorticoids are the preferred treatment for patients with persistent asthma at all levels of severity”.^{19,20} To help health care professionals bridge the gap between current knowledge and practice, the NHLBI’s NAEPP has prepared clinical guidelines for the management of asthma.²¹ An updated guideline is also available for the treatment of asthma in pregnancy.²²

In addition, the 2008 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend the addition of inhaled corticosteroids (ICS) to long-acting beta₂-agonists (LABA), in addition to other treatment options for patients with severe to very severe COPD. An inhaled glucocorticoid in combination with a long-acting beta agonist is more effective than the individual components in reducing exacerbations and improving lung function and health status. Two available combinations include budesonide/formoterol (Symbicort) and fluticasone/salmeterol (Advair). Both products are FDA-approved for use in the maintenance treatment of asthma and COPD.

**Stepwise Approach for Managing Persistent Asthma from the NAEPP Expert Panel
Report-3²³**

Severity of asthma	Adults and children ≥ 12 years
Step 6 Persistent Asthma	high-dose ICS AND LABA AND oral corticosteroid Consider omalizumab for patients who have allergies
Step 5 Persistent Asthma	high-dose ICS AND LABA Consider omalizumab for patients who have allergies
Step 4 Persistent Asthma	medium-dose ICS AND LABA Alternative: Medium-dose ICS + either leukotriene receptor antagonist (LTRA), theophylline, or zileuton
Step 3 Persistent Asthma	low-dose ICS AND LABA OR medium-dose ICS Alternative: Low-dose ICS + either LTRA, theophylline, or zileuton
Step 2 Persistent Asthma	low-dose ICS Alternative: cromolyn, LTRA, nedocromil, or theophylline
Step 1 Intermittent Asthma	no daily medications needed short acting inhaled beta ₂ -agonist (SABA) as needed

LABA = long acting beta₂-agonist

LTRA = leukotriene receptor antagonist or leukotriene modifier

ICS = inhaled corticosteroid

SABA = short acting beta₂-agonist

All asthma patients should have a short-acting beta₂-agonist inhaler for use on an as-needed basis.

**Stepwise Approach for Managing Persistent Asthma from the NAEPP Expert Panel
Report-3²⁴**

Severity of asthma	Children from birth to four years of age	Children five to 11 years of age
Step 6 Persistent Asthma	high-dose ICS AND LABA OR montelukast (Singular [®]) AND oral corticosteroid	high-dose ICS AND LABA AND oral corticosteroid Alternative: high-dose ICS PLUS either LTRA OR theophylline PLUS oral corticosteroids
Step 5 Persistent Asthma	high-dose ICS AND LABA OR montelukast (Singular)	high-dose ICS AND LABA Alternative: high-dose ICS AND LTRA OR theophylline
Step 4 Persistent Asthma	medium-dose ICS AND LABA OR montelukast (Singular)	medium-dose ICS AND LABA Alternative: medium-dose ICS AND LTRA OR theophylline
Step 3 Persistent Asthma	medium-dose ICS	low-dose ICS AND LABA OR LTRA OR theophylline OR medium-dose ICS
Step 2 Persistent Asthma	low-dose ICS Alternative: cromolyn or montelukast (Singular)	low-dose ICS Alternative: cromolyn, LTRA, nedocromil, or theophylline
Step 1 Intermittent Asthma	no daily medications needed Short acting Beta ₂ -agonist as needed	no daily medications needed Short acting Beta ₂ -agonist as needed

The 2007 GINA guidelines recommend a classification based on level of asthma control.²⁵ The GINA guidelines offer a stepwise treatment approach to achieving control using the patient's current level of control as the start point. If the patient is not controlled on the current regimen, treatment should be stepped up until control is achieved. If control is maintained for at least three months on the current regimen, treatment can be stepped down to the lowest step and dosage that maintains control. The NAEPP Expert Panel Report-3 report released in 2007 also recommends a similar evaluation of control and adjusting therapy up or down to achieve control.²⁶

In 2008, the GINA guidelines were updated to produce a more streamlined, user-friendly document that emphasizes the importance of asthma control with appropriate treatment. The

asthma classification system is defined in terms of three levels of control: controlled, partly controlled, or uncontrolled. Roles of several medications used to treat asthma (e.g. leukotriene modifiers, long acting beta agonists, cromones and inhaled glucocorticoids) have evolved since prior versions of the guidelines and have been included in the 2008 update.²⁷ More specifically, use of the long-acting beta₂-agonists only in combination with appropriately dosed inhaled corticosteroids for the treatment of asthma was emphasized.

Levels of Asthma Control from 2008 GINA guidelines²⁸

Characteristic	Controlled (all of the following)	Partly controlled (any present in past week)	Uncontrolled
Daytime symptoms	None (≤ two times per week)	> Two times per week	Three or more features of partly controlled asthma in any week
Limitations of activities	None	Any	
Nocturnal symptoms/awakening	None	Any	
Need for reliever/rescue treatment	None (≤ two times per week)	> Two times per week	
Lung function (PEF or FEV1)	Normal	<80% predicted or personal best	
Exacerbations	None	One or more per year	One in any week

Stepwise Approach to Asthma Control from 2008 GINA guidelines²⁹

	Adults and children six years of age and older
Step 1	As-needed reliever medication Recommended: rapid acting beta ₂ -agonist Alternatives: inhaled anticholinergic, short-acting oral beta ₂ -agonist or short-acting theophylline
Step 2	One controller AND an as-needed reliever medication Recommended controller: low-dose ICS Alternative controller: leukotriene modifier
Step 3	One or two controllers AND an as-needed reliever medication Recommended for adolescents and adults: low-dose ICS AND LABA Recommended for children but particularly children five years of age and younger: medium-dose ICS Alternative controllers: medium or high-dose ICS, low-dose ICS AND leukotriene modifier, OR, low-dose sustained-release theophylline
Step 4	Two or more controllers AND an as-needed reliever medication Recommended: medium- or high-dose ICS AND a long-acting beta ₂ - agonist Alternative controllers: leukotriene modifier OR sustained-release theophylline
Step 5	Additional controller options AND an as-needed reliever medication Recommended controllers for patients who remain severely uncontrolled on Step 4 medications: Oral corticosteroids Anti-IgE treatment [omalizumab – (Xolair®)]

Pharmacology

Corticosteroids decrease the metabolism of the anti-inflammatory compound arachidonic acid and reduce the synthesis of pro-inflammatory prostaglandins and leukotrienes. In addition, they increase the number and responsiveness of beta-adrenergic receptors. Corticosteroids block late-phase reaction to allergens, reduce airway hyperresponsiveness, and inhibit inflammatory cell migration and activation.³⁰ Because systemic corticosteroids have a high incidence of adverse reactions, inhaled corticosteroids are preferred for maintenance therapy of asthma.

Advair is a combination product containing a long-acting beta₂-agonist, salmeterol DPI (Serevent) and a corticosteroid, fluticasone. Symbicort, is a combination product also containing a long-acting beta₂-agonist, formoterol MDI (Foradil[®]) and a corticosteroid, budesonide. Both selectively bind to the beta₂-receptors in the bronchial smooth muscle, leading to bronchial relaxation and a decrease in the release of mediators of immediate hypersensitivity from mast cells.

Delivery and Deposition

The selection of a delivery system is a critical factor in determining clinical success of inhaled corticosteroid therapy. Delivery systems can significantly affect both topical and systemic activity of inhaled corticosteroids.^{31,32} Poor inhaler technique has been reported in up to 89 percent of patients.³³

Metered dose inhalers (MDIs) are pressurized spray inhalers, available in suspension and solution, for which the user has to press down on the metal canister to release the medicine and then inhale. MDIs deliver approximately 15 to 35 percent of the administered dose to the lungs. Spacer chambers can be attached to MDIs to make them easier to use by people who find it hard to coordinate the press-and-breathe action. When using the spacer, the user can take several breaths to inhale the medicine, which is held in the chamber, so that it is more likely that the right amount of medicine will reach the airways. There are currently two inhalers that are still in the CFC MDI formulation, Azmacort and Aerobid/Aerobid M. The FDA has granted an extension until December 31, 2009 for these products to be discontinued or reformulated.

Dry-powder inhalers (DPIs) are breath-actuated devices that release the medicine in the form of a dry powder when the user breathes in. Each manufacturer uses a different brand of DPI for their individual products. Although DPIs minimize the potential difficulties in coordinating the press-and-breathe action of the MDI, these delivery systems tend to result in more dosage variations than MDIs at low inspiratory flow rates (less than 20 L/min).

Nebulizer therapy is not the recommended form of administration for most patients.³⁴ It is considered inferior to an MDI with spacer because of the inconvenience, decreased drug deposition, higher risk of side effects and potentially higher cost. It may be considered an alternative in cases where patients lack the coordination to use the MDI with spacer particularly in the very young and the very old.

Pharmacokinetics

Several comparative studies have demonstrated that, when given in equipotent anti-inflammatory doses, fluticasone (Flovent) and budesonide (Pulmicort) have less systemic effect, as measured by plasma cortisol, than the other agents.^{35,36,37,38,39} There is, however, considerable intersubject variability in the rate of absorption of these agents from the lungs.⁴⁰

The NAEPP guidelines provide information regarding the relative potencies and dosages of each of the available agents.⁴¹ It should be noted that these are not the FDA-approved doses, but rather those doses shown to be clinically effective and recommended by the NHLBI.

Ciclesonide (Alvesco) was approved after the release of the 2007 NAEPP report and is therefore not contained in the comparative chart below. However, the GINA guidelines were updated in 2008.

NAEPP Expert Panel Report-3 Estimated Comparative Daily Dosages for Inhaled Corticosteroids (mcg/day)^{42,43}

Drug	Adults and Children ≥12 Years of Age			Children (five to 11 years of age)		
	Low-dose	Medium-dose	High-dose	Low-dose	Medium-dose	High-dose
beclomethasone HFA (QVAR)	80-240	240-480	>480	80-160	160-320	>320
budesonide DPI (Pulmicort)	180-600	>600-1,200	>1,200	180-400	400-800	>800
flunisolide MDI (Aerobid, -M)	500-1,000	1,000-2,000	>2,000	500-750	1,000-1,250	>1,250
fluticasone HFA MDI (Flovent HFA)	88-264	264-440	>440	88-176	>176-352	>352
mometasone DPI (Asmanex Twisthaler)	200	400	>400	n/a	n/a	n/a
triamcinolone MDI (Azmacort)	300-750	>750-1,500	>1,500	300-600	>600-900	>900

Most of these agents are recommended for twice daily use. The exceptions to this are mometasone (Asmanex DPI), which can be dosed once daily, and triamcinolone (Azmacort MDI), which is usually given three to four times daily, although some patients may respond to twice daily dosing.

GINA Guidelines for Equipotent Dosages of Inhaled Corticosteroids (mcg/day):⁴⁴

Drug	Adults			Children		
	Low-dose	Medium-dose	High-dose	Low-dose	Medium-dose	High-dose
beclomethasone MDI (QVAR)	200-500	>500-1,000	>1,000-2,000	100-200	>200-400	>400
budesonide DPI (Pulmicort)	200-400	>400-800	>800-1,600	100-200	>200-400	>400
budesonide respules (Pulmicort Respules)	--	--	--	250-500	>500-1,000	>1,000
ciclesonide MDI (Alvesco)	80-160	>160 - 320	>320 – 1,280	80-160	>160 - 320	>320
flunisolide MDI (Aerobid, -M)	500-1,000	>1,000-2,000	>2,000	500-750	>750-1,250	>1,250
fluticasone MDI (Flovent)	100-250	>250-500	>500-1,000	100-200	>200-500	>500
mometasone DPI (Asmanex)	200-400	>400-800	>800-1,200	100-200	>200-400	>400
triamcinolone MDI (Azmacort)	400-1,000	>1,000-2,000	>2,000	400-800	>800-1,200	>1,200

Onset of Action

Drug	Onset of action	Maximum benefit
Corticosteroids		
beclomethasone MDI (QVAR) ⁴⁵	one to two weeks	three to four weeks
budesonide DPI (Pulmicort Flexhaler) ⁴⁶	24 hours	one to two weeks
budesonide suspension (Pulmicort Respules) ⁴⁷	two to eight days	four to six weeks
ciclesonide MDI (Alvesco) ⁴⁸	--	four weeks or longer
flunisolide MDI (Aerobid) ⁴⁹	one to four weeks	--
fluticasone MDI (Flovent HFA) ⁵⁰	24 hours – variable time to onset	one to two weeks or longer
fluticasone powder for inhalation (Flovent Diskus) ⁵¹	24 hours – variable time to onset	one to two weeks or longer
mometasone DPI (Asmanex) ⁵²	one to 2.5 hours	one to two weeks or longer
triamcinolone MDI (Azmacort) ⁵³	one week	two weeks or longer

Corticosteroid/Bronchodilator combinations		
Drug	Onset of action	Maximum benefit
budesonide/formoterol MDI (Symbicort) ⁵⁴	15 minutes	two weeks or longer
fluticasone/salmeterol DPI (Advair Diskus) ⁵⁵	30 – 60 minutes	one week or longer
fluticasone/salmeterol MDI (Advair HFA) ⁵⁶	30 – 60 minutes	one week or longer

Contraindications/Warnings^{57,58,59,60,61,62,63,64,65,66,67}

All of these agents are contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

A black box warning exists for all long-acting beta agonists (e.g. salmeterol and formoterol) as well as all combination products that contain them [e.g. fluticasone/salmeterol (Advair HFA, Advair Diskus) and budesonide/formoterol (Symbicort)]. For Advair Diskus, Advair HFA and Symbicort, the boxed warning, Risk of Asthma-Related Deaths, states the following:

- Long-acting beta₂-adrenergic agonists may increase the risk of asthma-related deaths. A US study showed an increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13,176 patients treated for 28 weeks on salmeterol versus three out of 13,179 patients on placebo).
- When treating patients with asthma, Advair Diskus, Advair HFA or Symbicort should be prescribed for only those patients not adequately controlled on other asthma-controller medications or whose disease severity clearly warrants initiation of treatment with two maintenance therapies.

Drug Interactions^{68,69,70,71,72,73,74,75,76,77,78}

The main route of metabolism for many corticosteroids is via the cytochrome P450 isoenzyme 3A4. Inhibitors of CYP3A4 (ritonavir, ketoconazole, itraconazole, clarithromycin, erythromycin) may increase the plasma concentration of inhaled corticosteroids. Fluticasone (Flovent) use in combination with ritonavir has been associated with systemic corticosteroid effects such as Cushing’s syndrome and adrenal suppression.

Adverse Effects

Drug	Cough	Headache	Nausea	Oral candidiasis	Pharyngitis	Upper respiratory infection
Corticosteroids						
beclomethasone MDI (QVAR) ⁷⁹	1-3	12	1	0	8	9
budesonide DPI (Pulmicort Flexhaler) ⁸⁰	nr	nr	1.8	1.3	2.7	2.2
budesonide suspension (Pulmicort Respules) ⁸¹	5-9	≥3	nr	nr	≥3	34-38
ciclesonide MDI (Alvesco) ⁸²	< 1	4.9-11	< 1	< 1	7-10.5	4.1-8.7
flunisolide MDI (Aerobid, Aerobid-M) ⁸³	3-9	25	25	3-9	1-3	25
fluticasone powder for inhalation (Flovent Diskus) ⁸⁴	1-5	2-14	1-8	>1-9	3-22	14-21
fluticasone MDI (Flovent HFA) ⁸⁵	4-6	5-11	reported	2-5	1-3	16-18
mometasone DPI (Asmanex) ⁸⁶	nr	20-22	1-3	4-6	8-13	8-15
triamcinolone MDI (Azmacort) ⁸⁷	reported	7-21	nr	reported	7-25	nr
Corticosteroid/Bronchodilator Combinations						
budesonide/formoterol MDI (Symbicort) ⁸⁸	≤3	6.5	1.4	1.4	≥1 - < 3	7.6
fluticasone/salmeterol DPI (Advair Diskus) ⁸⁹	3-6	12-13	4-6	1-4	10-13	21-27
fluticasone/salmeterol MDI (Advair HFA) ⁹⁰	reported	21	5	1-3	nr	16

Adverse effects are reported as a percentage. Adverse effects are obtained from package inserts and are not meant to be comparative. nr = not reported.

In 2006, the FDA updated the safety information for combination products containing salmeterol (Serevent), including fluticasone/salmeterol (Advair Diskus, and Advair HFA). Product safety information for formoterol (Foradil) was updated in 2006. The combination product budesonide/formoterol (Symbicort) also has this warning. The labeling for these products contains a boxed warning about a small, but significant, increased risk of life-threatening asthma episodes or asthma related deaths observed in patients taking salmeterol in the recently completed Salmeterol Multicenter Asthma Research Trial (SMART). In the prematurely stopped study, only the single component agent, salmeterol, was administered. Post-hoc analysis indicates that the risk of these serious reactions was significantly higher in African-Americans. The FDA does note that the benefits of salmeterol in patients with COPD or asthma outweigh the risks.⁹¹

Special Populations^{92,93,94,95,96,97,98,99,100,101,102}

Pediatrics

Safety and effectiveness of fluticasone/salmeterol (Advair HFA), budesonide/formoterol (Symbicort), and ciclesonide (Alvesco) in children under age 12 has not been proven. Safety and effectiveness of triamcinolone (Azmacort), budesonide (Pulmicort Flexhaler) and flunisolide (Aerobid, Aerobid-M) in children under age six has not been proven. Beclomethasone (QVAR) in children under age five has not been proven safe or effective. Fluticasone/salmeterol (Advair Diskus) and fluticasone (Flovent HFA, Flovent Diskus) in children under age four has not been proven safe or effective. Mometasone (Asmanex) is approved for maintenance treatment of asthma for children age four years and older.

Budesonide respules (Pulmicort Respules) are indicated specifically for children between twelve months and eight years of age.

Pregnancy

All products in this category are Pregnancy Category C except budesonide (Pulmicort), which is Pregnancy Category B.

Hepatic Impairment

Close monitoring of patients using fluticasone/salmeterol (Advair) who have hepatic impairment is recommended due to accumulation of both active ingredients.

Dosages

Drug	Adult doses		Pediatric doses		Availability
	Initial	Maximum	Initial	Maximum	
Corticosteroids					
beclomethasone MDI (QVAR) ¹⁰³	40 -80 mcg twice daily (previous bronchodilator use alone) 40 -160 twice daily (previous inhaled corticosteroid therapy)	320 mcg twice daily	40 mcg twice daily	80 mcg twice daily	40 mcg and 80 mcg MDI with HFA propellant (100 actuations per canister)
budesonide DPI (Pulmicort Flexhaler) ¹⁰⁴	360 mcg twice daily	720 mcg twice daily	180 mcg twice daily	360 mcg twice daily	90 mcg and 180 mcg DPI (120 actuations per canister)
budesonide suspension (Pulmicort Respules) ¹⁰⁵	--	--	250-500 mcg twice daily or 250-1,000 mcg once daily	250-500 mcg twice daily or 500-1,000 mcg once daily	250, 500, 1,000 mcg per 2 mL Respule® via jet nebulizer
ciclesonide MDI (Alvesco) ¹⁰⁶	80 mcg twice daily (patients who received bronchodilator alone)	160 mcg twice daily	12 years and older: 80 mcg twice daily (patients who received bronchodilator alone)	160 mcg twice daily	80 mcg or 160 mcg MDI with HFA propellant (80 mcg is available as 60 actuations per canister) (160 mcg MDI is available as 60 or 120 actuations per canister)
	80 mcg twice daily (patients who received inhaled corticosteroid)	320 mcg twice daily	12 years and older: 80 mcg twice daily (patients who received inhaled corticosteroid)	320 mcg twice daily	
	320 mcg twice daily (patients who received oral corticosteroids)	320 mcg twice daily	12 years and older: 120 mcg twice daily (patients who received oral corticosteroid)	320 mcg twice daily	
flunisolide MDI (Aerobid, Aerobid-M) ¹⁰⁷	500 mcg twice daily	1,000 mcg twice daily	500 mcg twice daily	500 mcg twice daily	250 mcg MDI with three CFC propellants (100 actuations per canister)

Dosages (continued)

Drug	Adult doses		Pediatric doses		Availability
	Initial	Maximum	Initial	Maximum	
Corticosteroids					
fluticasone MDI (Flovent HFA) ¹⁰⁸	88 mcg twice daily (patients who received bronchodilator alone)	440 mcg twice daily	four to 11 years: 88 mcg twice daily	four to 11 years: 88 mcg twice daily	44, 110, 220 mcg MDI with HFA propellant (120 actuations per canister)
	88-220 mcg twice daily (patients who used inhaled corticosteroids)	440 mcg twice daily			
	440 mcg twice daily (patients who used oral corticosteroids)	880 mcg twice daily			
fluticasone powder for inhalation (Flovent Diskus) ¹⁰⁹	100 mcg twice daily (patients who received bronchodilators alone)	500 mcg twice daily	four to 11 years: 50 mcg twice daily (when prior therapy is with bronchodilator alone or inhaled corticosteroid)	four to 11 years: 100 mcg twice daily	50 mcg, 100 mcg, 250 mcg blister units (60 blisters per pack)
	100-250 mcg twice daily (patients who used inhaled corticosteroids)	500 mcg twice daily			
	500-1,000 mcg twice daily (patients who used oral corticosteroids)	1,000 mcg twice daily			

Dosages (continued)

Drug	Adult doses		Pediatric doses		Availability
	Initial	Maximum	Initial	Maximum	
Corticosteroids					
mometasone DPI (Asmanex Twisthaler) ¹¹⁰	220 mcg daily in evening (if on bronchodilator alone or inhaled corticosteroid) or 440 mcg twice daily (if on oral corticosteroid)	440 mcg daily (single or divided doses) or 880 mcg daily	12 years and older: 220 mcg daily in evening (if on bronchodilator alone or inhaled steroid) or 440 mcg twice daily (if on oral corticosteroid) 4 to 11 years of age: 110 mcg once daily in the evening	12 years and older: 440 mcg daily (single or divided doses) or 880 mcg daily 4 to 11 years of age: 110 mcg once daily in the evening	110 & 220 mcg DPI (Available in 100 & 200 actuations per unit, respectively)
triamcinolone MDI (Azmacort) ¹¹¹	150 mcg three to four times daily or 300 mcg twice daily	1,200 mcg daily	75-150 mcg three to four times daily or 150-300 mcg twice daily	900 mcg daily	60 mg per 20 gram canister Note: 200 mcg from the valve and 75 mcg from the spacer mouthpiece per actuation (240 actuations per canister)

Dosages (continued)

Drug	Adult doses		Pediatric doses		Availability
	Initial	Maximum	Initial	Maximum	
Corticosteroid/Bronchodilator Combinations					
budesonide/formoterol MDI (Symbicort) ¹¹²	80 mcg/ 4.5 mcg twice daily to 160 mcg/ 4.5 mcg twice daily	160 mcg/ 4.5 mcg twice daily	12 years and older: 80 mcg/ 4.5 mcg twice daily to 160 mcg/ 4.5 mcg twice daily	12 years and older: 160 mcg/ 4.5 mcg twice daily	80/4.5 and 160/4.5 mcg/actuation MDI with HFA propellant (120 actuations per canister) Dose counter available for all strengths
fluticasone/salmeterol DPI (Advair Diskus) ¹¹³	100 mcg/ 50 mcg twice daily to 500 mcg/ 50 mcg twice daily	500 mcg/ 50 mcg twice daily	<u>4-11 years</u> 100 mcg/ 50 mcg twice daily	--	100/50, 250/50 and 500/50 mcg/actuation Diskus [®] DPI (60 blisters)
fluticasone/salmeterol MDI (Advair HFA) ¹¹⁴	45 mcg/ 21 mcg twice daily 115 mcg/ 21 mcg twice daily 230 mcg/ 21 mcg twice daily	230 mcg/ 21 mcg twice daily	12 years and older: 45 mcg/ 21 mcg twice daily 115 mcg/ 21 mcg twice daily 230 mcg/ 21 mcg twice daily	12 years and older: 230 mcg/ 21 mcg twice daily	45/21, 115/21 and 230/21 mcg/actuation MDI with HFA propellant (120 actuations per canister) Dose counter available for all strengths

Clinical Trials

Search Strategy

Articles were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the use of all drugs in this class. Randomized, controlled, comparative trials are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance.

Asthma

beclomethasone MDI (QVAR) versus fluticasone/salmeterol DPI (Advair)

In an evaluation of step-down therapy, 39 patients with uncontrolled moderate-to-severe asthma were treated with beclomethasone MDI 1,000 mcg twice daily for four weeks and then randomized to medium-dose beclomethasone MDI 200 mcg twice daily or low-dose fluticasone/salmeterol DPI 100/50 mcg twice daily for eight weeks in a double-blind, double-dummy, parallel-group design.¹¹⁵ The primary outcome was the provocative dose of methacholine producing a 20 percent fall in forced expiration volume in the first second (FEV₁) (methacholine PD20). Secondary outcomes were lung function, surrogate inflammatory markers, diary card responses, QoL, and safety. There was a 0.9 doubling dose improvement in methacholine PD20 comparing asthma before versus after beclomethasone. Beclomethasone maintained this improvement, whereas fluticasone/salmeterol produced a further improvement, amounting to a significant 1.1 doubling dose difference at eight weeks for fluticasone/salmeterol versus beclomethasone. Suppression of plasma and urinary cortisol and serum osteocalcin levels occurred with beclomethasone DPI, but values returned to baseline levels within one month of beclomethasone or fluticasone/salmeterol administration.

budesonide DPI (Pulmicort) versus fluticasone/salmeterol DPI (Advair)

A randomized, double-blind study compared the efficacy and tolerability of low-dose fluticasone/salmeterol 100/50 mcg twice daily with medium-dose budesonide 400 mcg twice daily in 349 patients with symptomatic, mild to moderate asthma.¹¹⁶ After 12 weeks of treatment, patients in the fluticasone/salmeterol arm had a mean morning peak expiratory flow (PEF) of 426 L/min and evening PEF of 435 L/min compared to 415 L/min and 424 L/min in the budesonide group (p=0.022 and p=0.008, respectively). There were no differences in any other efficacy or tolerability parameters (symptom scores, use of rescue medication, spirometry, exacerbations).

budesonide DPI (Pulmicort) / formoterol DPI (Foradil) versus fluticasone/salmeterol DPI (Advair)

In the Evaluation of Different Inhaled Combination Therapies (EDICT) trial, medium-dose fluticasone/salmeterol DPI 250/50 mcg twice daily was compared with formoterol DPI 12 mcg twice daily and high-dose budesonide DPI 800 mcg twice daily given concurrently.¹¹⁷ The 428 patients in this study were moderate-to-severe, symptomatic asthmatics who were uncontrolled on existing corticosteroid therapy. This study used a randomized, double-blind, double-dummy, parallel-group design, consisting of a two-week run-in period on current corticosteroid therapy (1,000 to 1,600 mcg/day of beclomethasone or equivalent) and a 12-week treatment period. Improvement in mean morning PEF was similar in both groups and, like mean evening PEF, increased by a clinically significant amount (more than 20 L/min) from baseline in each treatment group. The mean rate of exacerbations was significantly lower in the fluticasone/salmeterol group compared with the budesonide/formoterol group (0.472 versus 0.735, respectively; p<0.001). Patients in the fluticasone/salmeterol group also experienced significantly fewer nocturnal symptoms, with a higher median percentage of symptom-free nights (p=0.04), nights with a symptom score less than two (p=0.03), and nights with no awakenings (p=0.02). Both treatments were well tolerated, with a similar low incidence of adverse events.

budesonide/formoterol MDI (Symbicort) versus budesonide DPI (Pulmicort)

A double-blind, randomized, parallel-group study was conducted to compare the efficacy and safety of low-dose budesonide/formoterol 80/4.5 mcg twice daily versus low-dose budesonide 200 mcg twice daily in 467 adult patients with mild to moderate asthma not fully controlled on low-dose inhaled corticosteroid use alone.¹¹⁸ Improvements were maintained over the 12 weeks of the study in asthma control days (17 percent increase in budesonide/formoterol patients versus 10 percent in budesonide patients), greater reduction in reliever medication use and symptom-free days in patients using budesonide/formoterol. Mean PEF after 12 weeks was 378 and 388 in the morning and evening, respectively per budesonide/formoterol group, while the budesonide-alone group was 369 and 381 in the morning and evening, respectively (p=0.002 and p=0.001 for morning and evening, respectively).

budesonide/formoterol MDI (Symbicort) versus budesonide DPI (Pulmicort) versus formoterol MDI (Foradil) versus budesonide (Pulmicort)+formoterol (Foradil) versus placebo

A 12-week, randomized, double-blind, double-dummy, placebo-controlled study was conducted to compare the efficacy and safety of budesonide/formoterol to each of its individual ingredients [budesonide, formoterol, or budesonide + formoterol] as well as to placebo.¹¹⁹ Five hundred ninety-six patients ages 12 years and older with moderate to severe persistent asthma and previously receiving an inhaled corticosteroid were placed on budesonide 160 mcg twice daily. After two weeks, they were randomized to budesonide/formoterol 160/4.5 mcg twice daily; budesonide 160 mcg twice daily + formoterol 4.5 mcg twice daily; budesonide 160 mcg twice daily; formoterol 4.5 mcg twice daily; or placebo twice daily. The primary efficacy endpoints were mean change from baseline of FEV₁ and mean change from baseline in 12-hour FEV₁. The results were similar in the budesonide/formoterol and the budesonide + formoterol groups in all measures. The budesonide/formoterol group showed greater improvement in FEV₁ (p≤0.049) than the individual budesonide, formoterol, and placebo. Also, fewer patients on budesonide/formoterol experienced worsening asthma symptoms (p≤0.025). All of the treatments were well tolerated with similar safety profiles.

budesonide/formoterol MDI (Symbicort) versus formoterol MDI (Foradil) versus terbutaline (Brethine)

In a 12-month, double-blind, parallel-group study of 3,394 patients (aged 12 years or older) maintained on budesonide/formoterol 160/4.5 mcg twice daily, the efficacy and safety of three reliever strategies were compared: terbutaline 0.4 mg daily, formoterol 4.5 mcg daily and budesonide/formoterol 160/4.5 mcg daily.¹²⁰ The primary outcome was time to first severe exacerbation, defined as an event resulting in hospitalization, ER visit or both, or the need for oral corticosteroids for three days or more. The time to first severe exacerbation was longer with as-needed budesonide/formoterol versus formoterol. The rate of severe exacerbations was 37, 29, and 19 per 100 patients per year with as-needed terbutaline, formoterol, and budesonide/formoterol, respectively. Asthma control days increased to a similar extent in all treatment groups. As-needed formoterol did not significantly improve symptoms compared with as-needed terbutaline. All treatments were well tolerated.

fluticasone (Flovent) versus fluticasone/salmeterol (Advair)

A one-year, randomized, stratified, double-blind, parallel-group study of 3,421 patients with uncontrolled asthma compared fluticasone and fluticasone/salmeterol in achieving guideline-based measures of control: totally and well-controlled asthma.¹²¹ Treatment was stepped-up until total control was achieved (or maximum 500 mcg corticosteroid twice a day). Significantly

more patients in each stratum (previously corticosteroid-free, low- and moderate-dose corticosteroid users) achieved control with fluticasone/salmeterol than fluticasone. Total control was achieved across all strata in 31 percent versus 19 percent of patients after dose escalation ($p < 0.001$) and 41 percent versus 28 percent of patients at one year for fluticasone/salmeterol and fluticasone, respectively. Asthma became well controlled in 63 percent versus 50 percent after dose escalation ($p < 0.001$) and in 71 percent versus 59 percent of patients at one year. Control was achieved more rapidly and at a lower corticosteroid dose with fluticasone/salmeterol versus fluticasone. Across all strata, 68 percent and 76 percent of the patients receiving fluticasone/salmeterol and fluticasone, respectively, were on the highest dose at the end of treatment. Exacerbation rates (0.07-0.27 per patient per year) and improvement in health status were significantly better with fluticasone/salmeterol.

fluticasone DPI (Flovent) versus salmeterol DPI (Serevent) versus fluticasone/salmeterol DPI (Advair)

In a double-blind, parallel-group, placebo-controlled study, 1,465 patients with COPD were randomized to receive salmeterol 50 mcg twice daily, high-dose fluticasone 500 mcg twice daily, fluticasone/salmeterol 500/50 mcg twice daily, or placebo.¹²² After 12 months, all active treatments improved lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations. Combination therapy improved pretreatment FEV₁ significantly more than did placebo (treatment difference 133 mL, 95% CI 105-161, $p < 0.0001$), salmeterol (73 mL, 46-101, $p < 0.0001$), or fluticasone alone (95 mL, 67-122, $p < 0.0001$). Combination treatment produced a clinically significant improvement in health status and the greatest reduction in daily symptoms. All treatments were well tolerated with no difference in the frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration.

A 12-week, randomized, double-blind study was conducted in patients 12 years and older ($n = 267$) with persistent asthma who were symptomatic while taking as-needed, short-acting beta₂-agonists alone.¹²³ Treatments were administered twice daily via the fluticasone/salmeterol Diskus device: salmeterol 50 mcg; low-dose fluticasone 100 mcg; or fluticasone 100 mcg with salmeterol 50 mcg. At end point, fluticasone/salmeterol were significantly ($p \leq 0.02$) more effective than the individual agents used alone in improving morning and evening peak expiratory flow rate and asthma symptoms. In addition, fluticasone and salmeterol effectively reduced rescue albuterol use ($p \leq 0.04$).

fluticasone/salmeterol DPI (Advair) versus budesonide/formoterol MDI (Symbicort)

A double-blind, double-dummy study compared the efficacy of stable versus adjusted doses of inhaled corticosteroid plus long-acting beta-agonists. The study was conducted in 688 adult patients with persistent asthma and a mean FEV₁ of 81 percent.¹²⁴ Initially, patients were randomized to receive either fluticasone/salmeterol 250 mcg/50 mcg one inhalation twice daily or budesonide/formoterol 200 mcg/6 mcg two inhalations twice daily. After four weeks of this stable dosing, 581 patients (about 15 percent discontinuation rate) in both groups continued for an additional 48 weeks on either a stable dose of fluticasone/salmeterol or an adjustable dosing regimen of budesonide/formoterol that required either halving the dose and stepping up or down as indicated by presence or absence of nocturnal awakenings due to asthma, frequency of rescue medication use, and changes in morning PEF. The primary endpoint was the percentage of symptom-free days. Patients receiving stable-dosed fluticasone/salmeterol had a significantly greater percentage of symptom-free days compared to those receiving adjustable budesonide/formoterol (58.8 versus 52.1 percent; $p = 0.034$) and experienced fewer emergency

room visits/hospitalizations (0.18 versus 0.33; $p=0.008$). Patients in the adjustable budesonide/formoterol group used an average of 1.8 inhalations daily with nearly 83 percent ($n=235$) stepping down to one inhalation daily. The results suggest that there is a minimum daily amount of maintenance therapy necessary to prevent exacerbations in adults with persistent asthma.

In a follow-up study to the CONCEPT trial, the long-term efficacy (including symptom-free days and exacerbations) as well as impact on health-related QoL of the stable-dose regimen of fluticasone/salmeterol and the adjustable maintenance dosing regimen of budesonide/formoterol were evaluated.¹²⁵ A total of 568 patients completed the Asthma Quality of Life Questionnaire (AQLQ) at least once during the study. The mean change from baseline in AQLQ overall score was not significantly greater at 52 weeks with fluticasone/salmeterol than with budesonide/formoterol ($p=0.121$). However, a post hoc regression analysis did identify a statistically significant difference in AQLQ score of a 0.5 point improvement in overall score at both 28 and 52 weeks, respectively ($p=0.038$ and $p=0.009$).

The efficacy of high-dose salmeterol/fluticasone plus a short-acting beta-agonist was compared to budesonide/formoterol maintenance and reliever therapy.¹²⁶ The study consisted of 2,309 patients aged 12 years old with an FEV₁ 50% of predicted who experienced an asthma exacerbation in the previous year. Patients were randomized to receive budesonide/formoterol 160/4.5 mcg (two inhalations twice daily and as needed) or salmeterol/fluticasone 50/500 mcg (one inhalation twice daily), plus terbutaline as needed, for six months. Budesonide/formoterol maintenance and reliever therapy reduced total exacerbations from 31 to 25 events/100 patients/year ($p=0.039$), and exacerbations requiring hospitalization/emergency room treatment from 13 to eight events/100 patients/year ($p=0.046$). The treatments showed no difference in measures of lung function or asthma symptoms and were both well tolerated. Also, the mean dose of inhaled corticosteroid was lower using budesonide/formoterol maintenance and reliever therapy (792 mcg/day budesonide [1,238 mcg/day beclomethasone dipropionate equivalent]) versus 1,000 mcg/day fluticasone [2,000 mcg/day beclomethasone equivalent] with salmeterol/fluticasone therapy; $p<0.0001$). In the treatment of uncontrolled asthma, budesonide/formoterol maintenance and reliever therapy reduces incidence of severe asthma exacerbations and hospitalizations/ER treatment with similar daily symptom control (and less inhaled corticosteroid exposure) compared with sustained salmeterol/fluticasone with short-acting beta-agonist.

budesonide/formoterol MDI (Symbicort) versus budesonide (Pulmicort) versus formoterol (Foradil) versus placebo

A 12-week, multicenter, double-blind, randomized, placebo-controlled, double-dummy study was conducted in 480 patients age 12 years or older with mild to moderate persistent asthma treated with inhaled corticosteroids for four weeks or more and with an FEV₁ of 60 to 90 percent.¹²⁷ After a two-week washout period, patients received either budesonide/formoterol 80/4.5 twice daily ($n=123$), budesonide 80 mcg twice daily ($n=121$), formoterol 4.5 mcg twice daily ($n=114$), or placebo ($n=122$). At the end of treatment, greater increases in FEV₁ occurred in the budesonide/formoterol group versus all of the other groups (0.37 versus 0.23, 0.17, and 0.03 L, respectively; $p<0.005$). Fewer patients receiving budesonide/formoterol withdrew due to worsening asthma versus the formoterol (42.1 and 18.4 percent) and placebo (56.6 versus 32.8 percent) groups. However, the results were similar, according to the authors, with respect to worsening asthma between the budesonide/formoterol and budesonide groups (21.5 versus 6.6 percent). The authors determined that in adults and adolescents with mild to moderate

persistent asthma that twice daily budesonide/formoterol resulted in improved pulmonary function versus its component ingredients alone. All of the study drugs were well tolerated.

A 12-week, randomized, double-blind, double-dummy, placebo-controlled, multicenter trial of 596 adult patients (ages 12 and older) with moderate to severe persistent asthma was conducted to evaluate patient reported outcomes (PROs) related to asthma therapy.¹²⁸ Patients received budesonide 160 mcg twice daily for the first two weeks. They were then randomized to receive two inhalations twice daily of one of five treatment arms: budesonide/formoterol 160/4.5 mcg; budesonide 160 mcg plus formoterol DPI 4.5 mcg; budesonide 160 mcg; formoterol DPI 4.5 mcg; or placebo. The primary endpoints were PROs using the standardized Asthma Quality of Life Questionnaire (AQLQ[S]), Medical Outcomes Survey (MOS) Sleep Scale, Patient Satisfaction With Asthma Medication (PSAM) questionnaire, diary data, and global assessments. Patients receiving budesonide/formoterol reported significantly greater improvements from baseline on the AQLQ(S) and asthma control variables (based on symptoms and rescue medication use; all $p < 0.001$) versus placebo.

mometasone furoate DPI (Asmanex) versus placebo

A 12-week, multicenter, double-blind, parallel-group, placebo-controlled study evaluating two dosing regimens of mometasone (100 mcg every evening and 100 mcg twice daily) in 296 children ages four to 11 years of age with asthma and prior use of inhaled corticosteroids.¹²⁹ The primary efficacy variable was the change in FEV₁ from baseline to endpoint. The average change in the daily dose was 4.73 points while the twice daily dose was 5.52 points ($p < 0.002$). The active treatments did not differ from placebo in adverse event reporting.

mometasone furoate DPI (Asmanex) versus budesonide DPI (Pulmicort) versus placebo

An eight-week, multicenter, placebo-controlled, double-blind, double-dummy study was conducted in 262 patients (12 years of age or older) with moderate persistent asthma to compare the safety and efficacy of once daily mometasone DPI to budesonide DPI and placebo.¹³⁰ Patients were randomized to once daily morning treatment with mometasone 440 mcg, low-dose budesonide 400 mcg, or placebo. The primary efficacy endpoint was percent change in FEV₁ from baseline to the final evaluable visit. At endpoint, the FEV₁ was significantly greater ($p < 0.01$) in the mometasone group (8.9 percent) than both the budesonide group (2.1 percent) and placebo group (-3.9 percent). Secondary efficacy variables including morning and evening PEF rates, albuterol use, percentage of asthma symptom-free days, and physician-evaluated response to therapy were also significantly improved at endpoint in the mometasone group compared with both the placebo and budesonide groups ($p < 0.05$). Both active treatments were well tolerated.

ciclesonide MDI (Alvesco) versus budesonide DPI (Pulmicort)

A 12-week, multicenter, randomized study to compare the efficacy of ciclesonide to budesonide enrolled 544 patients ages 12 to 75 years.¹³¹ Patients were randomized to receive inhaled ciclesonide 80 or 320 micrograms daily or budesonide 200 micrograms twice daily for 12 weeks. This study was designed in a double-blind manner with respect to the ciclesonide dose and open-label for budesonide because a budesonide placebo was not available. Efficacy and tolerability assessments were performed at baseline and weeks four, eight, and twelve. The primary end point was the change from baseline in FEV₁ at 12 weeks. Secondary endpoints included changes from baseline in morning peak expiratory flow (PEF), asthma symptom scores, and rescue medication use. The results of this study in patients with primarily mild to

moderate asthma suggest that patients using either dose of ciclesonide (80 or 320 micrograms daily) had similar improvements in pulmonary function, control of asthma symptoms, and reduced need for rescue medications as those patients who received budesonide 200 micrograms twice daily.

Another study was designed to compare the efficacy and safety of once daily ciclesonide (320 mcg) to once daily budesonide (320 mcg) in patients with persistent asthma for 12 weeks after a four to six week pre-treatment period with budesonide.¹³² Patients with an increase in FEV₁ of seven percent were randomized to ciclesonide 320 mcg or budesonide 320 mcg once daily in the morning for 12 weeks. Change in FEV₁ was the primary endpoint and actually decreased in both groups. The authors state that for FEV₁, ciclesonide was noninferior to budesonide (0.18 L versus 0.23 L, respectively). For forced vital capacity improvement, ciclesonide was statistically superior to budesonide (0.12 L versus 0.21 L, p=0.010). Asthma symptom scores were comparable; the median percentage of symptom-free days was significantly higher for ciclesonide (43.6 percent) versus budesonide (25.8 percent, p=0.017). Rescue medication use decreased significantly only for ciclesonide patients (p=0.009). Frequency of adverse events was low in both groups.

ciclesonide MDI (Alvesco) versus fluticasone (Flovent)

A 12-week, double-blind, parallel-group study compared the efficacy and safety of once daily ciclesonide and twice daily fluticasone in patients ages 12 to 75 years with persistent asthma.¹³³ Patients were randomized to once daily ciclesonide 80 mcg (n=278), ciclesonide 160 mcg (n=271), or twice daily fluticasone 88 mcg (n=259). Significant improvements from baseline were seen in all three treatment groups for FEV₁, asthma symptom scores, and rescue medication use (all p<0.0001). Asthma exacerbation rates were low. Adverse event reporting indicated good tolerability of all treatments.

COPD

budesonide/formoterol (Symbicort) versus budesonide (Pulmicort) versus formoterol (Foradil) versus placebo

In a 12-month, randomized, double-blind, placebo-controlled, parallel-group study in 812 adults (mean age 64 years, mean FEV₁ 36 percent), patients with moderate to severe COPD received two inhalations twice daily of either budesonide/formoterol 160/4.5 mcg, budesonide 200 mcg, formoterol 4.5 mcg or placebo.¹³⁴ Severe exacerbations and FEV₁ were the primary variables. Other variables including peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever beta₂-agonist and safety variables were recorded. Budesonide/formoterol reduced the mean number of severe exacerbations per patient per year by 24 percent versus placebo and 23 percent versus formoterol. FEV₁ increased by 15 percent versus placebo and nine percent versus budesonide. Morning PEF improved significantly on day one versus placebo and budesonide. After one week, morning PEF was improved versus placebo, budesonide and formoterol. Improvements in morning and evening PEF versus comparators were maintained over 12 months. Budesonide/formoterol decreased all symptom scores and use of reliever beta₂-agonists significantly versus placebo and budesonide, and improved HRQL versus placebo. All treatments were well tolerated.

budesonide/formoterol (Symbicort) versus fluticasone/salmeterol (Advair) versus salbutamol versus placebo

In a double-blind, double-dummy, crossover study, 90 patients (age 40 years and older; FEV₁ 30 to 70 percent) were randomized to a single dose (two inhalations) of budesonide/formoterol 160/4.5 mcg, fluticasone/salmeterol 250/25 mcg, salbutamol 100 mcg or placebo on four visits.¹³⁵ Outside the United States albuterol is known as salbutamol. The primary end-point was change in FEV₁ five minutes after drug inhalation; secondary end-points included inspiratory capacity (IC) and perception of onset of effect. Budesonide/formoterol significantly improved FEV₁ at five minutes compared with placebo (p<0.0001) and fluticasone/salmeterol (p=0.0001). Significant differences were first observed at three minutes. Onset of effect was similar with budesonide/formoterol and salbutamol. Improvements in FEV₁ following active treatments were superior to placebo after 180 min (all p<0.0001); both combinations were better than salbutamol at maintaining FEV₁ improvements (p≤0.0001) at 180 minutes. Active treatments improved IC at 15 and 185 minutes compared with placebo (p<0.0001). Maximal IC was greater with budesonide/formoterol than salmeterol/fluticasone (p=0.0184) at 65 minutes. Patients reported a positive response to the perceptions of the onset of effect question shortly after receiving active treatments (median time to onset was five minutes for active treatments versus 20 minutes for placebo), with no significant difference between active treatments. Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than fluticasone/salmeterol and similar to salbutamol.

Clinical Trials: Safety

There is concern that prolonged treatment with high doses of inhaled corticosteroids may have a detrimental effect on bone mineral density (BMD), cause ocular toxicity, suppress the adrenal/pituitary axis and inhibit vertical growth.

budesonide (Pulmicort Respules) versus reference treatments

Pooled safety data from budesonide inhalation suspension studies (n=2,356) found there were small differences in short-term growth velocity between children who received budesonide inhalation suspension and those who received reference treatment in two of five trials that evaluated this variable.¹³⁶ No posterior subcapsular cataracts were reported in any study. The frequencies of oropharyngeal events and infection with budesonide inhalation suspension were comparable with those of reference treatments. No increased risk of varicella or upper respiratory tract infection was apparent, and budesonide inhalation suspension did not cause significant adrenal suppression in studies assessing this variable.

Data from the inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study evaluated the safety of once-daily budesonide use over three years in patients aged five to 66 years with mild, persistent asthma (n=7,221).¹³⁷ The most commonly reported events included respiratory infections, rhinitis, pharyngitis, bronchitis, viral infections, and sinusitis. Fewer asthma-related, serious adverse events were reported with budesonide (2.2 percent) compared with placebo (3.8 percent). Oral candidiasis was reported more frequently with budesonide (1.2 percent) than with placebo (0.5 percent).

A further analysis of the START trial was conducted to determine whether severe asthma exacerbations are associated with a persistent decline in lung function.¹³⁸ There were 315 patients who experienced at least one severe asthma exacerbation, of which 305 were

analyzable, 190 in the placebo group and 115 in the budesonide group. In the placebo group, the change in post-bronchodilator FEV₁ percent predicted from baseline to the end of the study, in patients who did or did not experience a severe exacerbation was -6.44 percent and -2.43 percent, respectively (p<0.001). A significant difference was seen in both children and in adults, but not in adolescents. In the budesonide group, the change in the post-bronchodilator FEV₁ percent predicted in patients who did or did not experience a severe exacerbation was -2.48 percent and -1.72 percent, respectively (p=0.57). The difference in magnitude of reduction afforded by budesonide, in patients who experienced at least one severe asthma-related event compared with those who did not, was statistically significant (p=0.042). Severe asthma exacerbations are associated with a more rapid decline in lung function. Treatment with low doses of inhaled corticosteroid is associated with an attenuation of the decline.

fluticasone (Flovent) versus placebo

A randomized, double-blind, placebo-controlled study of 160 patients with asthma who had minimal previous exposure to corticosteroids was performed to evaluate the effects of treatment with fluticasone versus placebo on bone, hypothalamic-pituitary-adrenal (HPA) axis function, and the eyes in patients with asthma.¹³⁹ Patients received low-dose fluticasone at 88 mcg twice daily, high-dose fluticasone at 440 mcg twice daily, or placebo twice daily for two years. Long-term treatment with 88 mcg of fluticasone twice daily was comparable to placebo in all skeletal, ophthalmic, and HPA axis function assessments. Treatment with fluticasone at 440 mcg twice daily resulted in no significant effects on bone mineral density and a statistically significant, but not clinically important, temporary reduction in cortisol production.

fluticasone MDI (Flovent) versus budesonide MDI (Pulmicort)

Forty children (age one to three years) with mild asthma were studied in a three-way crossover, randomized, placebo-controlled, double-blind trial.¹⁴⁰ Treatment with medium-dose fluticasone MDI 200 mcg twice daily was compared with low-dose budesonide MDI 200 mcg twice daily and placebo, all given via a spacer device. Systemic steroid activity was assessed after one and four weeks of treatment by measured increase in lower-leg length. The increases in lower-leg length during placebo, budesonide, and fluticasone treatments were 85, 45, and 34 mcm/day, respectively. Compared to placebo, the growth in lower-leg length was significantly reduced from both corticosteroid treatments. The differences between budesonide and placebo (40 mcm/day) and between fluticasone and placebo (51 mcm/day) were statistically significant. The difference between the two active treatment groups, fluticasone and budesonide, was not statistically significant.

fluticasone/salmeterol DPI (Advair) and fluticasone DPI (Flovent)

A randomized, multicenter, double-blind, active-controlled, parallel-group study in 203 children with persistent asthma who were symptomatic during inhaled corticosteroid therapy were examined to compare the safety of twice-daily treatment of inhaled fluticasone/salmeterol with that of fluticasone alone.¹⁴¹ The subjects received either fluticasone/salmeterol (100/50 mcg) or low-dose fluticasone (100 mcg) alone twice daily for 12 weeks. The results of the study showed that the safety profile of fluticasone/salmeterol was comparable to that of fluticasone alone with the overall incidence of adverse events being 59 percent for fluticasone/salmeterol and 57 percent for fluticasone. The changes in heart rate, blood pressure, and laboratory variables were infrequent and similar between both groups, and no patients had clinically significant abnormal electrocardiographic findings during treatment. The incidence of withdrawals within the study due to asthma exacerbations was two percent in the fluticasone/salmeterol group and

five percent in the fluticasone group. Therefore, the study concluded that in children with persistent asthma, fluticasone/salmeterol twice daily was well tolerated, with a safety profile similar to that of fluticasone used alone.

budesonide DPI (Pulmicort) versus fluticasone DPI (Flovent)

The systemic effects of high-dose budesonide 1,600 mcg/day and high-dose fluticasone 1,500 mcg/day were compared in a randomized, double-blind, cross-over study of 60 adult patients with moderate to severe asthma not controlled on high-dose beclomethasone or budesonide.¹⁴² HPA axis suppression of the two treatment groups was assessed by morning serum cortisol and 12-hour nocturnal urinary cortisol excretion measured at the end of each treatment period. Neither treatment produced significant suppression of either parameter compared to baselines. The ratio between the AUC serum cortisol measured after fluticasone treatment and after budesonide treatment was 0.99, indicating equivalent effects on the HPA axis. Two exacerbations of acute asthma occurred during budesonide treatment and none during fluticasone treatment. Both treatments were well tolerated.

Bone Mineral Density and Fracture

Several studies have been performed to evaluate the relative effects of the various agents on bone mass and metabolism.

A multicenter, double-blind, parallel-group study randomized 69 mild to moderate asthmatic adults to treatment with medium or high doses of fluticasone or beclomethasone.¹⁴³ After one year, there was no loss of trabecular or integral bone in the distal radius or tibia in any of the patients.

In a randomized, double-blind, placebo-controlled trial, the authors recruited 412 current smokers or recent quitters with mild to moderate COPD.¹⁴⁴ They used inhaled triamcinolone 600 mcg or placebo twice daily. Femoral neck and lumbar spine BMD were measured at baseline and again after one and three years. Serum osteocalcin was measured at baseline, three months, one year, and three years. After three years, BMD at the femoral neck decreased 1.78 percent more with inhaled corticosteroid than with placebo ($p < 0.001$). More participants in the inhaled corticosteroid group experienced six percent or more loss of femoral neck BMD ($p = 0.002$). Lumbar spine BMD increased in the placebo group by 0.98 percent but decreased by 0.35 percent in the inhaled corticosteroid group (a difference of -1.33 percent, $p = 0.007$). Changes in osteocalcin did not correlate with changes in BMD. Fractures, lost height, or osteoporosis diagnoses were not increased among inhaled corticosteroid users compared with placebo users.

Linear Growth

Evidence on growth velocity and height over an extended time period is available from the Childhood Asthma Management Program (CAMP) trial that compared budesonide with nedocromil and placebo in 1,041 children followed for four to six years.¹⁴⁵ A difference consistent with the above magnitude occurred during the first year of the study. However, in long-term follow up, the difference in growth velocity was not maintained, and all groups had similar growth velocity at the end of treatment. There was still a one centimeter difference between the study groups at the end of treatment. A slight difference in bone age suggests the potential for catch-up for the inhaled corticosteroid group. An ancillary study of the CAMP trial demonstrated that low-dose budesonide 400 mcg/day over a three-year period had no effects

on HPA axis function in children with mild to moderate asthma.¹⁴⁶ Growth in children taking corticosteroids by any route should be carefully monitored.

Meta-Analyses

In 2007, a meta-analysis of randomized trials in children and adults was completed comparing fluticasone to either beclomethasone or budesonide in the treatment of chronic asthma.¹⁴⁷ Two reviewers independently assessed articles for inclusion and methodological quality. Seventy-one studies (14,602 participants) representing 74 randomized comparisons met the inclusion criteria. When compared at a fluticasone-to-budesonide or beclomethasone dose ratio of 1:2, fluticasone produced a significantly greater end of treatment FEV₁ (0.04 L (95% CI, 0 to 0.07 L), end of treatment and change in morning PEF. However, there was no significant change in FEV₁ or evening PEF. This applied to all drug doses, age groups, and delivery devices. No difference between fluticasone and beclomethasone or budesonide were seen for trial withdrawals. Fluticasone led to fewer symptoms and less rescue medication use. There was a greater likelihood of pharyngitis (hoarseness) with fluticasone when compared to budesonide or beclomethasone with no difference in the likelihood of oral candidiasis. When comparing the doses of these agents in a dose ratio of 1:1, fluticasone produced a statistically significant difference in morning PEF, evening PEF, and FEV₁ over both budesonide and beclomethasone. The effects on exacerbations were mixed. There were no significant differences in the incidence of hoarseness, pharyngitis, candidiasis, or cough at the equivalent dose ratio.

A meta-analysis of published and unpublished literature evaluated the impact of long-term inhaled corticosteroid use on bone density in adult patients with asthma or COPD.¹⁴⁸ The authors found that long-term use was not associated with significant changes in bone density.

Data from the United Kingdom based General Practice Research Database have been evaluated to determine whether children or adolescents exposed to inhaled corticosteroids are at a higher risk of having bone fractures compared with non-exposed individuals.¹⁴⁹ The authors concluded that they were not.

Summary

When used in equivalent dosages, efficacy among all inhaled corticosteroids is similar. There are differences among the agents in dosage frequency and the number of inhalations needed for each dose. Most of these agents are recommended for twice daily use. The exceptions to this are mometasone (Asmanex Twisthaler DPI), which can be dosed once daily, and triamcinolone (Azmacort MDI), which is usually given 3-4 times daily, although some patients may respond to twice daily dosing. Also, there are two agents that act as prodrugs, ciclesonide (Alvesco) and beclomethasone (QVAR). They are both converted either during absorption (QVAR) or by esterases in the lung (Alvesco).

The use of a combination long acting beta agonist and an inhaled glucocorticoid (e.g. salmeterol/fluticasone (Advair) and formoterol/budesonide (Symbicort) in a single inhaler as both a controller and a reliever is effective in maintaining asthma control and reduces exacerbations that may otherwise require hospitalizations or oral glucocorticoids. In addition, while the combination may offer the specific benefit of increased compliance with therapy, there is limited ability to titrate the dose of each component independently.

When selecting an agent for an individual patient, consideration must be given to the characteristics of the particular delivery device and the necessary technique for its use. This is

particularly important for the very young and the very old. For children under five years of age, an MDI with a spacer and an optional face mask or mouthpiece may be preferable. If this is not effective, consideration could be given towards nebulizer therapy or a DPI is an alternative for individuals young and old who cannot use MDIs due to an inability to coordinate hand and press devices.

References

- ¹ QVAR [package insert]. Miami, FL; IVAX Laboratories, November 2006.
- ² Pulmicort Flexhaler [package insert]. Wilmington, DE; AstraZeneca; June 2008.
- ³ Aerobid / Aerobid-M [package insert]. St. Louis, MO; Forest Pharmaceuticals; November 2003.
- ⁴ Flovent Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁵ Flovent HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁶ Asmanex [package insert]. Kenilworth, NJ; Schering; February 2008.
- ⁷ Azmacort [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; September 2007.
- ⁸ Pulmicort Respules [package insert]. Wilmington, DE; AstraZeneca; June 2007.
- ⁹ Alvesco [package insert]. Florham Park, NJ; Nycomed US Inc.; May 2008.
- ¹⁰ Symbicort [package insert]. Wilmington, DE; AstraZeneca; July 2008.
- ¹¹ Advair Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; August 2008.
- ¹² Advair HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2008.
- ¹³ Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed March 2, 2009.
- ¹⁴ Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. *N Engl J Med*. 1991; 325:388-92.
- ¹⁵ Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. *Am J Respir Crit Care Med*. 1998; 157:S1-53.
- ¹⁶ Jeffery PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. *Am Rev Respir Dis*. 1992; 145:890-9.
- ¹⁷ Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. *Am Rev Respir Dis*. 1992; 145:669-74.
- ¹⁸ Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. *N Engl J Med*. 2000; 343:332-6.
- ¹⁹ Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2002.
- ²⁰ Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed March 2, 2009.
- ²¹ Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed March 2, 2009.
- ²² National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. *J Allergy Clin Immunol*. 2005; 115(1):34-46.
- ²³ *Update on Selected Topics 2002*; NAEPP Expert Panel Report-2. NIH Pub. 02-5075, www.NHLBI.nih.gov.
- ²⁴ *Update on Selected Topics 2002*; NAEPP Expert Panel Report-2. NIH Pub. 02-5075, www.NHLBI.nih.gov.
- ²⁵ Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2008. Available at: <http://www.ginasthma.com/Guidelineitem.asp?i1=2&i2=1&intId=60>. Accessed March 2, 2009.
- ²⁶ Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed March 2, 2009.
- ²⁷ Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2008. Available at: <http://www.ginasthma.com/Guidelineitem.asp?i1=2&i2=1&intId=60>. Accessed March 2, 2009.
- ²⁸ Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2008. Available at: <http://www.ginasthma.com/Guidelineitem.asp?i1=2&i2=1&intId=60>. Accessed March 2, 2009.
- ²⁹ Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2008. Available at: <http://www.ginasthma.com/Guidelineitem.asp?i1=2&i2=1&intId=60>. Accessed March 2, 2009.
- ³⁰ Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed March 2, 2009.
- ³¹ Kelly HW. Comparison of inhaled corticosteroids. *Ann Pharmacother*. 1998; 32:220-32.
- ³² Martin RJ, Szeffler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. *Am J Respir Crit Care Med*. 2002; 165:1377-836.
- ³³ McFadden Jr E. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. *Journal of Allergy and Clinical Immunology*. 1995; 96:278-283.
- ³⁴ Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2006.
- ³⁵ Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. *Am J Respir Crit Care Med*. 1998; 157:S1-53.
- ³⁶ Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. *Arch Intern Med*. 1999; 159:941-55.
- ³⁷ Kamada AK, Szeffler SJ, Martin RJ, et al. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. *Am J Respir Crit Care Med*. 1996; 153:1739-48.

- ³⁸ Brus R. Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults. *Arch Intern Med.* 1999; 159:1903-8.
- ³⁹ Martin RJ, Szeffler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. *Am J Respir Crit Care Med.* 2002; 165:1377-836.
- ⁴⁰ Minto C, Li B, Tattam B, et al. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation: intersubject variability in systemic absorption from the lung. *Br J Clin Pharmacol.* 2000; 50:116-24.
- ⁴¹ Available at: <http://www.nlm.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed March 2, 2009.
- ⁴² Available at: http://www.nlm.nih.gov/guidelines/asthma/08_sec4_lt_0-11.pdf. Accessed March 2, 2009.
- ⁴³ Available at: http://www.nlm.nih.gov/guidelines/asthma/09_sec4_lt_12.pdf. Accessed March 2, 2009.
- ⁴⁴ Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention.* Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2007. Updated December 2008. Available at: <http://www.ginasthma.com/Guidelineitem.asp?i1=2&i2=1&intId=60>. Accessed March 2, 2009.
- ⁴⁵ QVAR [package insert]. Miami, FL; IVAX Laboratories, November 2006.
- ⁴⁶ Pulmicort Flexhaler [package insert]. Wilmington, DE; AstraZeneca; June 2008.
- ⁴⁷ Pulmicort Respules [package insert]. Wilmington, DE; AstraZeneca, June 2007.
- ⁴⁸ Alvesco [package insert]. Florham Park, NJ; Nycomed US Inc.; May 2008.
- ⁴⁹ Aerobid [package insert]. St. Louis, MO; Forest Pharmaceuticals; November 2003.
- ⁵⁰ Flovent HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁵¹ Flovent Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁵² Asmanex [package insert]. Kenilworth, NJ; Schering; February 2008.
- ⁵³ Azmacort [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; September 2007.
- ⁵⁴ Symbicort [package insert]. Wilmington, DE; AstraZeneca; July 2008.
- ⁵⁵ Advair Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; August 2008.
- ⁵⁶ Advair HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2008.
- ⁵⁷ Advair Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; August 2008.
- ⁵⁸ Advair HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2008.
- ⁵⁹ Aerobid [package insert]. St. Louis, MO; Forest Pharmaceuticals; November 2003.
- ⁶⁰ Asmanex [package insert]. Kenilworth, NJ; Schering; February 2008.
- ⁶¹ Azmacort [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; September 2007.
- ⁶² Flovent HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; January 2007.
- ⁶³ Flovent Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁶⁴ Pulmicort Flexhaler [package insert]. Wilmington, DE; AstraZeneca; June 2008.
- ⁶⁵ Pulmicort Respules [package insert]. Wilmington, DE; AstraZeneca, June 2007.
- ⁶⁶ QVAR [package insert]. Miami, FL; IVAX Laboratories, November 2006.
- ⁶⁷ Symbicort [package insert]. Wilmington, DE; AstraZeneca; July 2008.
- ⁶⁸ Advair Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; August 2008.
- ⁶⁹ Advair HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2008.
- ⁷⁰ Aerobid [package insert]. St. Louis, MO; Forest Pharmaceuticals; November 2003.
- ⁷¹ Asmanex [package insert]. Kenilworth, NJ; Schering; February 2008.
- ⁷² Azmacort [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; September 2007.
- ⁷³ Flovent HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; January 2007.
- ⁷⁴ Flovent Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁷⁵ Pulmicort Flexhaler [package insert]. Wilmington, DE; AstraZeneca; June 2008.
- ⁷⁶ Pulmicort Respules [package insert]. Wilmington, DE; AstraZeneca, June 2007.
- ⁷⁷ QVAR [package insert]. Miami, FL; IVAX Laboratories, November 2006.
- ⁷⁸ Symbicort [package insert]. Wilmington, DE; AstraZeneca; July 2008.
- ⁷⁹ QVAR [package insert]. Miami, FL; IVAX Laboratories, November 2006.
- ⁸⁰ Pulmicort Flexhaler [package insert]. Wilmington, DE; AstraZeneca; June 2008.
- ⁸¹ Pulmicort Respules [package insert]. Wilmington, DE; AstraZeneca, June 2007.
- ⁸² Alvesco [package insert]. Florham Park, NJ; Nycomed US Inc.; May 2008.
- ⁸³ Aerobid [package insert]. St. Louis, MO; Forest Pharmaceuticals; November 2003.
- ⁸⁴ Flovent Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁸⁵ Flovent HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁸⁶ Asmanex [package insert]. Kenilworth, NJ; Schering; February 2008.
- ⁸⁷ Azmacort [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; September 2007.
- ⁸⁸ Symbicort [package insert]. Wilmington, DE; AstraZeneca; July 2008.
- ⁸⁹ Advair Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; August 2008.
- ⁹⁰ Advair HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2008.
- ⁹¹ Food and Drug Administration. FDA Talk Paper: Labeling Changes for Drug Products that Contain Salmeterol. August 2003.
- ⁹² Advair Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; August 2008.
- ⁹³ Advair HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2008.
- ⁹⁴ Aerobid [package insert]. St. Louis, MO; Forest Pharmaceuticals; November 2003.
- ⁹⁵ Asmanex [package insert]. Kenilworth, NJ; Schering; February 2008.
- ⁹⁶ Azmacort [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; September 2007.
- ⁹⁷ Flovent HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; January 2007.
- ⁹⁸ Flovent Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ⁹⁹ Pulmicort Flexhaler [package insert]. Wilmington, DE; AstraZeneca; June 2008.

- ¹⁰⁰ Pulmicort Respules [package insert]. Wilmington, DE; AstraZeneca, June 2007.
- ¹⁰¹ QVAR [package insert]. Miami, FL; IVAX Laboratories, November 2006.
- ¹⁰² Symbicort [package insert]. Wilmington, DE; AstraZeneca; July 2008.
- ¹⁰³ QVAR [package insert]. Miami, FL; IVAX Laboratories, November 2006.
- ¹⁰⁴ Pulmicort Flexhaler [package insert]. Wilmington, DE; AstraZeneca; June 2008.
- ¹⁰⁵ Pulmicort Respules [package insert]. Wilmington, DE; AstraZeneca, June 2007.
- ¹⁰⁶ Alvesco [package insert]. Florham Park, NJ; Nycomed US Inc.; May 2008.
- ¹⁰⁷ Aerobid [package insert]. St. Louis, MO; Forest Pharmaceuticals; November 2003.
- ¹⁰⁸ Flovent HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ¹⁰⁹ Flovent Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; July 2008.
- ¹¹⁰ Asmanex [package insert]. Kenilworth, NJ; Schering; February 2008.
- ¹¹¹ Azmacort [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; September 2007.
- ¹¹² Symbicort [package insert]. Wilmington, DE; AstraZeneca; July 2008.
- ¹¹³ Advair Diskus [package insert]. Research Triangle Park, NC; GlaxoSmithKline; August 2008.
- ¹¹⁴ Advair HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2008.
- ¹¹⁵ Fowler SJ, Currie GP, Lipworth BJ. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. *J Allergy Clin Immunol.* 2002; 109:929-35.
- ¹¹⁶ Johansson G, McIvor RA, D'Ambrosio FP, et al. Comparison of Salmeterol/Fluticasone Propionate Combination with Budesonide in Patients with Mild-to-Moderate Asthma. *Clin Drug Invest.* 2001; 21:633-642.
- ¹¹⁷ Ringdal N, Chuchalin A, Chovan L, et al. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. *Respir Med.* 2002; 96:851-61.
- ¹¹⁸ Laloo UG, Malolepsy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild to moderate asthma. *Chest.* 2003; 123:1480-1487.
- ¹¹⁹ Noonan M, Rosenwasser L, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomized clinical trial. *Drugs.* 2006; 66(17):2235-54.
- ¹²⁰ Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study. *Lancet.* 2006; 368(9537): 744-53.
- ¹²¹ Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. *Am J Respir Crit Care Med.* 2004; 170(8):836-44.
- ¹²² Calverley P. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet.* 2003; 361:449-56.
- ¹²³ Murray J, Rosenthal R, Somerville L, et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. *Ann Allergy Asthma Immunol.* 2004; 93(4):351-9.
- ¹²⁴ Fitzgerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. *Clin Ther.* 2005; 27(4):393-406.
- ¹²⁵ Price DB, Williams AE, Yoxall S. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. *Respir Res.* 2007; 8:46.
- ¹²⁶ Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. *Respir Med.* 2007; 101(12):2437-46.
- ¹²⁷ Corren J, Korenblat PE, Miller CJ, et al. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. *Clin Ther.* 2007; 29(5): 823-43.
- ¹²⁸ Chervinsky P, Baker J, Bensch G, et al. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. *Ann Allergy Asthma Immunol.* 2008; 101(5): 463-73.
- ¹²⁹ Berger WE, Milgrom H, Chervinsky P, et al. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. *Ann Allergy Asthma Immunol.* 2006; 97(5):672-80.
- ¹³⁰ Corren J, Berkowitz R, Murray J, et al. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. *Int J Clin Pract.* 2003; 57(7):567-72.
- ¹³¹ Hansel TT, Benezet O, Kafe H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. *Clin Ther.* 2006 Jun; 28(6): 906-20.
- ¹³² Boulet LP, Drollmann A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. *Respir Med.* 2006 May; 100(5): 785-94.
- ¹³³ Magnussen H, Hofman J, Staneta P, et al. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. *J Asthma.* 2007 Sep; 44(7): 555-63.
- ¹³⁴ Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. *Eur Respir J.* 2003; 21(1):74-81.
- ¹³⁵ Lindberg A, Szalai Z, Pullerits T, et al. Fast onset of effect of budesonide/formoterol versus fluticasone/salmeterol and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. *Respirology.* 2007; 12(5):732-9.
- ¹³⁶ Szeffler SJ, Lyzell E, Fitzpatrick S, et al. Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experience. *Ann Allergy Asthma Immunol.* 2004; 93(1):83-90.
- ¹³⁷ Sheffer AL, Silverman M, Woolcock AJ, et al. Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. *Ann Allergy Asthma Immunol.* 2005; 94(1):48-54.

- ¹³⁸ O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. *Am J Respir Crit Care Med.* 2009; 179(1): 19-24.
- ¹³⁹ Kemp JP, Osur S, Shrewsbury SB, et al. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial. *Mayo Clin Proc.* 2004; 79(4):458-66.
- ¹⁴⁰ Anhoj J, Bisgaard AM, Bisgaard H. Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. *Pediatrics.* 2002; 109:E40.
- ¹⁴¹ Malone R, LaForce C, Nimmagadda S, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. *Ann Allergy Asthma Immunol.* 2005; 95(1):66-71.
- ¹⁴² Ringdal N, Lundback B, Alton M, et al. Comparable effects of inhaled fluticasone propionate and budesonide on the HAP-axis in adult asthmatic patients. *Respir Med.* 2000; 94:482-9.
- ¹⁴³ Medici TC, Grebski E, Hacki M, et al. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomized parallel group study in adult asthmatic subjects. *Thorax.* 2000; 55:375-82.
- ¹⁴⁴ Scanlon PD, Connett JE, Wise RA, et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. *Am J Respir Crit Care Med.* 2004; 170(12):1302-9.
- ¹⁴⁵ The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. *N Engl J Med.* 2000; 343(15):1054-63.
- ¹⁴⁶ Bacharier LB, Raissy HH, Wilson L, et al. Long-term effect of budesonide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma. *Pediatrics.* 2004; 113(6):1693-9.
- ¹⁴⁷ Adams N, Lasserson T, Cates C, et al. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. *Cochrane Database Syst Rev.* 2007 (4): CD002310.
- ¹⁴⁸ Halpern MT, Schmier JK, Van Kerkhove MD, et al. Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. *Ann Allergy Asthma Immunol.* 2004; 92(2):201-7.
- ¹⁴⁹ Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. *Pediatrics.* 2004; 114(2):469-73.